Lianchun Xiao

Lianchun Xiao is a High Senior Professor at The University of Texas MD Anderson Cancer Center, where his research integrates oncology, radiation oncology, pharmacology, and surgical oncology, with a particular focus on urology and medicinal research. His recent work centers on novel immunotherapy combinations and targeted therapies across multiple malignancies. His latest publications include a Phase I-II trial of perioperative chemotherapy combined with atezolizumab and tiragolumab in localized esophageal and gastroesophageal junction adenocarcinoma, a Phase I trial of binimetinib plus hydroxychloroquine in metastatic pancreatic cancer, and investigations into the obesity paradox and predictive immune biomarkers in intrahepatic cholangiocarcinoma and fibrolamellar carcinoma. He has also explored the growth hormone pathway as a prognostic biomarker in unresectable hepatocellular carcinoma treated with radiation therapy, and conducted Phase 1/2 trials combining encorafenib, cetuximab, and nivolumab in BRAFV600E metastatic colorectal cancer, as well as sitravatinib plus nivolumab in metastatic clear cell renal cell carcinoma. His work bridges translational pharmacology and clinical trial design, advancing precision cancer care.